Form 4: Capricor Therapeutics CFO Exercises Stock Options

Anthony Bergmann, CFO of Capricor Therapeutics, exercised stock options to acquire 2,500 shares of common stock at $1.39 per share on March 3, 2025.

Summary

• On March 3, 2025, Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc., exercised stock options.
• This transaction resulted in the acquisition of 2,500 shares of common stock at a price of $1.39 per share.
• Following the transaction, Bergmann directly owns 8,223 shares of Capricor Therapeutics common stock.
• The stock options were originally granted on March 3, 2015, and adjusted due to a reverse stock split and share reprice.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of an executive exercising stock options, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The details provided are consistent with SEC regulations and reporting requirements.
• Similar filings are made by executives at companies like Amgen, Biogen, and Gilead Sciences when they exercise stock options or trade company shares.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and ownership.

Key Dates